非酒精性脂肪性肝病与阿尔茨海默病及血管病理影像和血浆生物标志物的纵向变化
研究纳入动脉粥样硬化风险社区研究中的1706名参与者,分析中年非酒精性脂肪性肝病与晚年阿尔茨海默病及血管神经病理血浆和脑MRI生物标志物变化的关系。结果显示中年非酒精性脂肪性肝病与晚年白质高信号体积更大、6年内白质高信号增长更快以及β-淀粉样蛋白42:40降低和颞顶叶皮层厚度变薄相关。
要点
- 中年非酒精性脂肪性肝病与晚年白质高信号体积更大及6年内增长更快相关。
- 中年非酒精性脂肪性肝病与中年和晚年β-淀粉样蛋白42:40降低相关。
- 中年非酒精性脂肪性肝病与晚年颞顶叶皮层厚度Meta感兴趣区降低相关。
核心结论
- 中年非酒精性脂肪性肝病与阿尔茨海默病及累积性血管病理相关,揭示肝功能与痴呆之间的潜在通路。
- 神经病理和神经元损伤的血浆生物标志物可能作为易于测量和动态的指标,用于监测肝功能受损对脑健康的影响。
研究设计与样本
- 研究纳入动脉粥样硬化风险社区研究中在2011-13年和2016-19年最多2次访视时进行脑MRI白质高信号体积和颞顶叶皮层厚度Meta感兴趣区测量的参与者,并在1993-95年、2011-13年和2016-19年最多3次测量血浆β-淀粉样蛋白42:40、苏氨酸181磷酸化tau和神经丝轻链生物标志物。
- 非酒精性脂肪性肝病使用1990-92年脂肪肝指数分类。
- 采用多变量线性回归分析中年非酒精性脂肪性肝病与阿尔茨海默病及血管神经病理血浆和脑MRI生物标志物变化之间的关联,主要模型调整人口学特征、载脂蛋白E、酒精使用和肾功能。
- 共纳入1706名参与者,平均年龄56岁,62%为女性,28%为黑人。
主要发现
- 中年非酒精性脂肪性肝病 vs 无非酒精性脂肪性肝病与晚年白质高信号体积更大相关(每标准差差异0.19,95% CI 0.06-0.31)。
- 中年非酒精性脂肪性肝病 vs 无非酒精性脂肪性肝病与6年内晚年白质高信号年变化更快相关(年变化差异,标准差0.28,95% CI 0.05-0.51),提示累积性血管病理。
- 中年非酒精性脂肪性肝病 vs 无非酒精性脂肪性肝病与中年阿尔茨海默病生物标志物相关:1993-95年测量的β-淀粉样蛋白42:40较低(标准差-0.21,95% CI -0.39至-0.04)。
- 中年非酒精性脂肪性肝病 vs 无非酒精性脂肪性肝病与晚年阿尔茨海默病生物标志物相关:2011-13年测量的β-淀粉样蛋白42:40较低(标准差-0.13,95% CI -0.23至-0.03)和颞顶叶皮层厚度Meta感兴趣区较低(标准差-0.16,95% CI -0.28至-0.05)。
- 中年非酒精性脂肪性肝病个体 vs 无中年非酒精性脂肪性肝病个体中年神经丝轻链较低,但非酒精性脂肪性肝病个体神经丝轻链增加速率更快且随时间加速。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Prospective measures of plasma and cerebral MRI biomarkers of Alzheimer disease (AD) and vascular neuropathology provide an opportunity to investigate possible mechanisms linking liver disease and dementia. We aimed to quantify the association of midlife nonalcoholic fatty liver disease (NAFLD) with change in plasma and brain MRI biomarkers of AD and vascular neuropathology. METHODS: We included participants from the Atherosclerosis Risk in Communities Study with brain MRI measurements of white matter hyperintensity (WMH) volume and temporal-parietal lobe cortical thickness meta region of interest (ROI) at up to 2 different visits, in 2011-13 and 2016-19, and plasma biomarkers of β-amyloid (Aβ)42:40, phosphorylated tau at threonine 181, and neurofilament light (NfL) were measured up to 3 times in 1993-95, 2011-13, and 2016-19. NAFLD was categorized using the fatty liver index in 1990-92. Multivariate linear regression was performed for associations between midlife NAFLD and change in plasma and brain MRI biomarkers of AD and vascular neuropathology. The primary models adjusted for demographics, Apolipoprotein E, alcohol use, and kidney function. RESULTS: Among 1,706 participants (mean age 56 years, 62% female, 28% Black), midlife NAFLD vs no NAFLD was associated with greater late-life WMH volume (difference per SD 0.19, 95% CI 0.06-0.31) and faster late-life WMH increase over 6 years (difference in annual change, SD 0.28, 95% CI 0.05-0.51), suggesting accumulating vascular pathology. Midlife NAFLD vs no NAFLD was also associated with AD biomarkers in midlife (lower Aβ42:40 [SD -0.21, 95% CI -0.39 to -0.04] measured in 1993-95) and late life (lower Aβ42:40 [SD -0.13, 95% CI -0.23 to -0.03] and lower temporal-parietal lobe cortical thickness meta ROI [SD -0.16, 95% CI -0.28 to -0.05] measured in 2011-13). Although midlife NfL was lower in individuals with vs without midlife NAFLD, those with NAFLD exhibited a faster rate of NfL increase that accelerated over time. DISCUSSION: Midlife NAFLD shows associations with AD and accumulating vascular pathology, revealing potential pathways linking liver function to dementia. Plasma biomarkers of neuropathology and neuronal injury may serve as easily measurable and dynamic indicators for monitoring the impacts of impaired liver function on brain health.
引用
- Lu Y, Pike JR, Hoogeveen R, et al. Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology. Neurology. 2024. PMID: 38471046. doi:10.1212/WNL.0000000000209203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。